Vyriad Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 90

Employees

  • Latest Deal Type
  • Series B1

  • Latest Deal Amount
  • $25M

  • Investors
  • 8

Vyriad General Information

Description

Developer of targeted genetic therapies using engineered viruses, viral vectors, and viral envelope glycoproteins to deliver genes directly to targeted cells. This technology facilitates oncolytic virotherapy, in vivo gene therapies, and editing applications, enabling clinicians with oncolytic viruses as monotherapies and in combination with immune-oncology drugs in multiple cancer indications.

Contact Information

Website
www.vyriad.com
Formerly Known As
Omnis Pharma, Magnis Therapeutics, Omnis International
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2900 37th Street Northwest
  • Building 110
  • Rochester, MN 55901
  • United States
+1 (507)
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • 2900 37th Street Northwest
  • Building 110
  • Rochester, MN 55901
  • United States
+1 (507)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vyriad Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series B1) 23-Dec-2025 $25M Completed Clinical Trials - Phase 2
9. Secondary Transaction - Private Completed Clinical Trials - Phase 2
8. Later Stage VC (Series B) 17-May-2022 Completed Clinical Trials - Phase 2
7. Early Stage VC (Series B) 14-Nov-2019 Completed Clinical Trials - Phase 1
6. Grant 18-Sep-2018 Completed Pre-Clinical Trials
5. Accelerator/Incubator Completed Pre-Clinical Trials
4. Grant 13-Apr-2018 Completed Pre-Clinical Trials
3. Grant 12-Apr-2017 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 01-Jan-2017 $10M $10M Completed Pre-Clinical Trials
1. Merger of Equals 18-Mar-2016 Completed Pre-Clinical Trials
To view Vyriad’s complete valuation and funding history, request access »

Vyriad Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-1
Series B
Series A 4,087,847 $0.000100 $2.51 $2.51 1x $2.51 5.89%
To view Vyriad’s complete cap table history, request access »

Vyriad Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of targeted genetic therapies using engineered viruses, viral vectors, and viral envelope glycoproteins to del
Biotechnology
Rochester, MN
90 As of 2025

Seattle, WA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vyriad Competitors (4)

One of Vyriad’s 4 competitors is Umoja Biopharma, a Venture Capital-Backed company based in Seattle, WA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Umoja Biopharma Venture Capital-Backed Seattle, WA
Intellia Therapeutics Formerly VC-backed Cambridge, MA
Sana Biotechnology Formerly VC-backed Seattle, WA
Kelonia Formerly VC-backed Boston, MA
To view Vyriad’s complete competitors history, request access »

Vyriad Patents

Vyriad Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026236565-A1 Oligomerization of glycoproteins and uses thereof Pending 07-May-2025
WO-2026236521-A1 Viral vectors, components thereof, and uses of the vectors and components thereof for production and delivery of a payload Pending 07-May-2025
WO-2026207502-A1 Immunological cells, uses thereof, and methods for in vivo delivery of chimeric antigen receptors Pending 27-Mar-2025
WO-2026187925-A1 Rous sarcoma virus virus-like particles, components thereof, and uses Pending 04-Mar-2025
WO-2026182903-A1 Methods and materials for treating cancer Pending 26-Feb-2025 A61K39/395
To view Vyriad’s complete patent history, request access »

Vyriad Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vyriad Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Mayo Clinic Ventures Corporate Venture Capital Minority
Mirae Asset Capital Venture Capital Minority
Stine Seed Company Corporation Minority
Regeneron Pharmaceuticals Corporation Minority
Southeast Minnesota Capital Fund Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Vyriad Acquisitions (2)

Vyriad’s most recent deal was a Merger of Equals with Magnis Therapeutics. The deal was made on 18-Mar-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Magnis Therapeutics 18-Mar-2016 Merger of Equals Biotechnology
Omnis Pharma 18-Mar-2016 Merger of Equals Biotechnology
To view Vyriad’s complete acquisitions history, request access »

Vyriad FAQs

  • When was Vyriad founded?

    Vyriad was founded in 2015.

  • Where is Vyriad headquartered?

    Vyriad is headquartered in Rochester, MN.

  • What is the size of Vyriad?

    Vyriad has 90 total employees.

  • What industry is Vyriad in?

    Vyriad’s primary industry is Biotechnology.

  • Is Vyriad a private or public company?

    Vyriad is a Private company.

  • What is the current valuation of Vyriad?

    The current valuation of Vyriad is .

  • What is Vyriad’s current revenue?

    The current revenue for Vyriad is .

  • How much funding has Vyriad raised over time?

    Vyriad has raised $113M.

  • Who are Vyriad’s investors?

    Mayo Clinic Ventures, Mirae Asset Capital, Stine Seed Company, Regeneron Pharmaceuticals, and Southeast Minnesota Capital Fund are 5 of 8 investors who have invested in Vyriad.

  • Who are Vyriad’s competitors?

    Umoja Biopharma, Intellia Therapeutics, Sana Biotechnology, and Kelonia are competitors of Vyriad.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process